🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excited to share our work from the #BRCABCYcollaboration presented at #SABCS24 now out in The Lancet Oncology: risk-reducing surgeries are associated with major survival improvement in young #BRCA carriers with #BreastCancer OncoAlert Eva Blondeaux Free link: urlsand.esvalabs.com/?u=https%3A%2F…

White smoke! The 133 Cardinal electors gathered in the Vatican’s Sistine Chapel have elected the new Pope. He will appear soon at the central window of St. Peter’s Basilica.

Although rare, in >150K osteoporosis pts, waiting ≥90 days after last IV bisphosphonate before dental extraction lowered jaw osteonecrosis risk (HR 0.57); even lower >1y (HR 0.43) rdcu.be/elB1X

Even if pCR is achieved after neoadj tx in TNBC pts, those with baseline TILs <30% and cN+ have worse prognosis. Should we consider escalation in the adj phase for this pt subgroup? #ESMOBreast25 #ESMOAmbassadors

This is a crucial issue that requires attention. Waiting an entire year for a response should not be acceptable, but unfortunately, it happens too often. In Latin America, only 14% of cancer research papers are published the same year they are completed. It is necessary to

Most oncologists would offer vaginal estrogen to breast cancer patients on endocrine therapy suffering from dryness, pain, frequent UTIs etc. We have very solid safety data for this.

Thematic take on ASCO breast cancer abstracts: 1. Move 'em up. DB09, ASCENT-04, SERENA-6 are really just trials of using agents earlier in the course of advanced disease. Since all patients with the right tumor subtype will eventually get the agent, the only real question is:

Destiny-Breast-09 will likely establish a new first-line therapy for HER2+ MBC. Here are my considerations going into #ASCO25 Patient population considerations: 1) De novo patients (capped at 50%): these patients are more likely to respond durably and possibly even be cured in

The most practice changing trial from #ASCO25 is now live on NEJM .If this was a drug, this would be approved today. Globally relevant and low-cost intervention that is not only delaying relapse but actually improving survival. Perfect case example of a #cancergroundshot trial.

Our review on key advancements in #liquidbiopsy in 2024 is finally out! This work was made possible thanks to the incredible team effort of the International Society of Liquid Biopsy Young Committee. 📰Check it out! ➡️ sciencedirect.com/science/articl…

🧬 The Liquid Biopsy Truth: What $40 Billion in Cancer Screening Really Buys Us A masterful The New Yorker investigation by Siddhartha Mukherjee reveals why finding cancer early isn't what we think it is. Here's what longevity clinics don't tell you... 🧵

🔥 Breakthrough in HR+HER2– Breast Cancer! 🧬 In I-SPY2 trial (n=395), ImPrint, an mRNA-based immune classifier, predicted response to neoadjuvant immunotherapy (IO) in high-risk HR+HER2– patients. 🔹 pCR with IO: ➡️ 75% in ImPrint+ vs 17% in ImPrint– ➡️ >90% pCR in best

New 📰: Low Allele Frequency Variants Identified on Germline Multi-Gene Panel Testing for Cancer Predisposition Can Suggest the Presence of Constitutional Mosaicism 🔓pubmed.ncbi.nlm.nih.gov/40260637/ ✍️Adela Rodríguez Hernández Brittany Bychkovsky, MD judy garber

A risk-reducing mastectomy is cost-effective for women aged 30 to 55 with a lifetime breast cancer risk of 35% or higher, regardless of carrying BRCA1, BRCA2, or PALB2 variants. ja.ma/46qoFXo